Orlando, FL -- (SBWIRE) -- 10/29/2013 -- Hot Stock Profits provides investors and traders with valuable trading tools and content as well as micro-cap stock alerts via eMail and text messages. To Join Our Text Message Alerts Service Just Text The Word Stocks To 555888 From Your Cell Phone. Our Focus Today Is On Idenix Pharmaceuticals Inc (NASDAQ:IDIX), Alexion Pharmaceuticals, Inc.(NASDAQ:ALXN).
Idenix Pharmaceuticals Inc (NASDAQ:IDIX) shares decreased 3% to $3.56 in the last trading session. The company announced that the Company's third quarter 2013 financial results will be released after close of market on Wednesday, October 30, 2013. Idenix management will host a conference call at 4:30 p.m. ET on Wednesday, October 30, 2013, to discuss the Company's financial results for the third quarter of 2013 and provide an update on the Company's development programs.
Additionally, the company on Oct. 1 announced a poster presentation featuring preclinical data for its uridine nucleotide prodrug candidate for the treatment of hepatitis C virus (HCV) infection at the 64th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), which will take place in Washington, DC, November 1-5, 2013.
Are investors worried about the recent updates with IDIX? Find out with a free trend analysis HERE
Alexion Pharmaceuticals, Inc.(NASDAQ:ALXN) shares declined 0.77% to $124.20. The company on Oct. 24 reported that its third-quarter net income increased to $93.8 million, or $0.47 per share, from $92.2 million, or $0.46 per share, last year. Adjusted net income was $167.9 million, or $0.83 per share, in the third quarter of 2013. Net product sales rose to $400.40 million, from $294.14 million, last year. Analysts expected the company to report profit per share of $0.79 on revenue of $395.29 million for the quarter.
Additionally, the company announced that researchers are scheduled to present data from clinical studies of Soliris® (eculizumab) in patients with atypical hemolytic uremic syndrome (aHUS), a genetic, life-long, ultra-rare disease associated with vital organ failure and premature death. Data will be presented at the annual meeting of the American Society of Nephrology (ASN), being held from November 5 -10, 2013 in Atlanta, Georgia.
Is ALXN going to continue its rally or drop like a rock? Find out with a free trend analysis HERE
Join Our Mobile SMS Alerts By Texting Stocks To 555888
HotStockProfits.com continuously monitors and scans the markets for day trading and swing trading signals on NASDAQ, NYSE, AMEX, OTCBB and Pink Sheet companies for its free e-newsletter subscribers.
HotStockProfits.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit HotStockProfits.com website, for complete risks and disclosures.
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)